VivaZome Therapeutics Pty Ltd (ABN 59 602 230 964) is a privately-held Australian biotech company, with headquarters at the La Trobe University Technology Enterprise Centre. VivaZome was formed to develop and commercialise exosome-based therapies for debilitating and/or life-threatening disorders, with an initial focus on critical limb ischaemia (CLI). CLI is a debilitating disease caused by reduced blood flow, most often in the legs. It affects more than 4 million people worldwide, with an estimated treatment cost of over $10B pa in the US alone. Existing treatments are largely surgical interventions including, in advanced disease, amputation. There is a huge need for new treatments, particularly pharmaceutical interventions to prevent or delay disease progression. VivaZome is developing new technologies and generating intellectual property and proprietary materials that are applicable generically to exosome therapies. They will also underpin the Company’s development of angiogenic exosomes for the treatment of CLI. The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech community.